	US 12,220,397 B2
	Brain health formulation
Scott Karolchyk, Denver, CO (US)
Assigned to MEDPHARM HOLDINGS, LLC, Denver, CO (US)
Filed by MEDPHARM HOLDINGS, LLC, Denver, CO (US)
Filed on Aug. 31, 2021, as Appl. No. 17/462,764.
Application 17/462,764 is a continuation in part of application No. 16/842,114, filed on Apr. 7, 2020, granted, now 11,723,892.
Claims priority of provisional application 62/830,939, filed on Apr. 8, 2019.
Prior Publication US 2021/0393578 A1, Dec. 23, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/352 (2006.01); A61K 9/107 (2006.01); A61K 31/045 (2006.01); A61K 31/047 (2006.01); A61K 31/05 (2006.01); A61K 36/534 (2006.01); A61K 47/24 (2006.01)

CPC A61K 31/352 (2013.01) [A61K 9/107 (2013.01); A61K 31/045 (2013.01); A61K 31/047 (2013.01); A61K 31/05 (2013.01); A61K 36/534 (2013.01); A61K 47/24 (2013.01)]

17 Claims

1. A formulation for improved brain health comprising: 5-50 mg cannabidiol (CBD); 5-25 mg tetrahydrocannabinol (THC); 5-25 mg tetrahydrocannabivarin (THC-V); 0.1-10 mg of at least one terpene; 1-20 mg of at least one antioxidant; 250-500 mg spearmint; and at least one emulsifier.